D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01565850 |
|
Recruitment Status :
Completed
First Posted : March 29, 2012
Results First Posted : April 11, 2016
Last Update Posted : April 11, 2016
|
Sponsor:
Gilead Sciences
Information provided by (Responsible Party):
Gilead Sciences
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naive adults as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Acquired Immunodeficiency Syndrome HIV Infections | Drug: D/C/F/TAF Drug: DRV Drug: COBI Drug: FTC/TDF Drug: D/C/F/TAF Placebo Drug: DRV Placebo Drug: COBI Placebo Drug: FTC/TDF Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 153 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults |
| Study Start Date : | April 2012 |
| Actual Primary Completion Date : | January 2013 |
| Actual Study Completion Date : | February 2014 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: D/C/F/TAF
D/C/F/TAF FDC tablet plus DRV placebo plus COBI placebo plus FTC/TDF placebo
|
Drug: D/C/F/TAF
DRV 800 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg FDC tablet administered orally once daily Drug: DRV Placebo DRV placebo tablet administered orally once daily Drug: COBI Placebo COBI placebo tablet administered orally once daily Drug: FTC/TDF Placebo FTC/TDF placebo tablet administered orally once daily |
|
Active Comparator: DRV+COBI+FTC/TDF
DRV tablet plus COBI tablet plus FTC/TDF 200/300 mg FDC tablet plus D/C/F/TAF placebo
|
Drug: DRV
DRV 800 mg (2 × 400 mg tablets) administered orally once daily
Other Name: Prezista® Drug: COBI COBI 150 mg tablet administered orally once daily
Other Names:
Drug: FTC/TDF FTC 200 mg/TDF 300 mg FDC tablet administered orally once daily
Other Name: Truvada® Drug: D/C/F/TAF Placebo D/C/F/TAF placebo tablet administered orally once daily |
Primary Outcome Measures :
- Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 [ Time Frame: Week 24 ]The snapshot algorithm was used which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Secondary Outcome Measures :
- Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 [ Time Frame: Week 48 ]The snapshot algorithm was used which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
- Change From Baseline in HIV-1 RNA at Week 24 [ Time Frame: Baseline; Week 24 ]
- Change From Baseline in HIV-1 RNA at Week 48 [ Time Frame: Baseline; Week 48 ]
- Change From Baseline in CD4+ Cell Count at Week 24 [ Time Frame: Baseline; Week 24 ]
- Change From Baseline in CD4+ Cell Count at Week 48 [ Time Frame: Baseline; Week 48 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adult (≥ 18 years) males or non-pregnant females
- Ability to understand and sign a written informed consent form
- General medical condition which does not interfere with the assessments and the completion of the trial
- Plasma HIV-1 RNA levels ≥ 5,000 copies/mL
- CD4+ cell count > 50 cells/µL
- Treatment-naive: No prior use of any approved or experimental anti-HIV drug for any length of time
- Screening genotype report must show sensitivity to DRV, TDF and FTC
- Normal ECG
- Adequate renal function: Estimated glomerular filtration rate ≥ 70 mL/min according to the Cockcroft Gault formula
- Hepatic transaminases ≤ 2.5 x upper limit of normal (ULN)
- Total bilirubin ≤ 1.5 mg/dL
- Serum amylase ≤ 5 x ULN
- Adequate hematologic function
- Normal thyroid-stimulating hormone (TSH)
- Females of childbearing potential must have a negative serum pregnancy test
- Females of childbearing potential must agree to utilize highly effective contraception methods from screening throughout the duration of study treatment and for 30 days following the last dose of study drugs
- Female subjects who are postmenopausal must have documentation of cessation of menses for ≥ 12 months and hormonal failure
- Female subjects who have stopped menstruating for ≥ 12 months but do not have documentation of ovarian hormonal failure must have a serum follicle stimulating hormone (FSH) level test
- Male subjects must agree to utilize a highly effective method of contraception during heterosexual intercourse throughout the study period and for 90 days following discontinuation of investigational medicinal product
Exclusion Criteria:
- A new AIDS defining condition diagnosed within the 30 days prior to screening
- Hepatitis B surface antigen positive
- Hepatitis C antibody positive
- Proven acute hepatitis in the 30 days prior to study entry
- Have a history or experiencing decompensated cirrhosis
- Current alcohol or substance use that potentially interferes with study compliance
- Any other clinical condition or prior therapy that would make the subject unsuitable for the study or unable to comply with the dosing requirements
- History of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma
- Females who are breastfeeding
- Positive serum pregnancy test (female of childbearing potential)
- Female subjects who utilize non-estrogen hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing
- Have an implanted defibrillator or pacemaker
- Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Baseline
- Participation in any other clinical trial without prior approval is prohibited while participating in this trial
- Receiving ongoing therapy with any of the disallowed medications, including drugs not to be used with darunavir and cobicistat
- Note: darunavir is a sulfonamide. Participants who previously experienced a sulfonamide allergy will be allowed to enter the trial. To date, no potential for cross sensitivity between drugs in the sulfonamide class and darunavir has been identified in patients participating in Phase 2 and Phase 3 trials.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01565850
Locations
Show 44 study locations
Sponsors and Collaborators
Gilead Sciences
Investigators
| Study Director: | Moupali Das, MD, MPH | Gilead Sciences |
| Responsible Party: | Gilead Sciences |
| ClinicalTrials.gov Identifier: | NCT01565850 |
| Other Study ID Numbers: |
GS-US-299-0102 |
| First Posted: | March 29, 2012 Key Record Dates |
| Results First Posted: | April 11, 2016 |
| Last Update Posted: | April 11, 2016 |
| Last Verified: | March 2016 |
Keywords provided by Gilead Sciences:
|
HIV-1 HIV Treatment-Naive |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Immunologic Deficiency Syndromes Blood-Borne Infections Communicable Diseases Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Immune System Diseases Slow Virus Diseases |
Darunavir Cobicistat Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-Infective Agents Anti-HIV Agents Anti-Retroviral Agents HIV Protease Inhibitors Viral Protease Inhibitors Protease Inhibitors Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors |